Follow The Filings

ENSC Ensysce Biosciences

Ensysce Biosciences earnings company data as of 4:47 AM ET 10/22

History

2 periods, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 13 Nov EPS — — —
Rev — — —
FY2026 Q2 13 Aug EPS — -0.20 —
Rev — — —

Insider trades

Open-market buys and sales by ENSC's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ENSC insider trades
  • $444K bought by 1 insider
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Bob G Gower Director
    Buy
    $444K 908,614 shares at $0.4900 +11182% to stake
    Traded Apr 23–Aug 7 Filed Aug 18

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
8-K/A 9.01
8-K 5.03,9.01
8-K 8.01
8-K 8.01
SCHEDULE 13D/A —
8-K 2.02,9.01
10-Q
8-K 1.01,2.01,3.02,3.03,5.02,5.03,7.01,9.01
8-K/A 9.01
8-K 5.02,9.01
8-K 3.01
8-K 2.02,9.01
10-Q
8-K 1.01,3.02,8.01,9.01
8-K 5.02,9.01
8-K 5.02,9.01
8-K 2.02,9.01
10-K
8-K 5.03,9.01
8-K 3.01
8-K 5.07
DEFA14A
DEF 14A
8-K 1.01,3.02,5.03,8.01,9.01
424B5

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.